2861205-06-1
Chemical Structure
Enlicitide decanoate
Synonym(s): MK-0616 decanoate
- CAS No.: 2861205-06-1
- Formula:C92H129FN14O17
- Molecular Weight:1722.09
InChIKey: ZMLCOVYFOZPADV-QQCDJELVSA-N
SMILES: O=C([C@@]1(C)N(C([C@H](CC2=CC=C(OC)C=C2)NC([C@H]([C@@H](C)O)NC3=O)=O)=O)CCC1)NCCC4=CC=C(CN(CCCCCCN5C6=C(C=C(F)C=C6)C7=C5)C(CCC(N[C@@H](C)C(N[C@H](CNC(CCCCC[N+](C)(C)C)=O)C(N[C@H](C(N[C@@H](C7)C(N([C@]38[H])CC[C@@H]8OCC9=O)=O)=O)CC%10=CC(CN9)=CC=C%10)=O)=O)=O)=O)C=C4.CCCCCCCCCC([O-])=O
Biological Activity: Enlicitide (MK-0616) decanoate is an orally active macrocyclic peptide PCSK9 inhibitor. Enlicitide decanoate binds to PCSK9, blocks its interaction with low-density lipoprotein receptor (LDLR), and enhances hepatic clearance of LDL-C. Enlicitide decanoate reduces atherogenic lipoproteins, including non-HDL cholesterol, apolipoprotein B, and lipoprotein (a). Enlicitide decanoate is applicable to research related to hypercholesterolemia, heterozygous familial hypercholesterolemia, and atherosclerotic cardiovascular disease[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Enlicitide decanoate | 99.82% | Enlicitide (MK-0616) decanoate is an orally active macrocyclic peptide PCSK9 inhibitor. Enlicitide decanoate binds to PCSK9, blocks its interaction with low-density lipoprotein receptor (LDLR), and enhances hepatic clearance of LDL-C. Enlicitide decanoate reduces atherogenic lipoproteins, including non-HDL cholesterol, apolipoprotein B, and lipoprotein (a). Enlicitide decanoate is applicable to research related to hypercholesterolemia, heterozygous familial hypercholesterolemia, and atherosclerotic cardiovascular disease. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
-
[1]. Elbahloul MA, et al. The Oral PCSK9 inhibitor enlicitide for hypercholesterolemia. Eur J Intern Med. 2026 Mar 14:106835.
[Content Brief] -
[2]. Merck. "Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Phase 3 CORALreef Lipids Trial." Merck, 8 Nov. 2025.
